Sempra (SRE) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual shareholders meeting scheduled for May 13, 2025, to be held virtually, with voting available online or by phone until May 12, 2025.
Shareholders are encouraged to review proxy materials and annual report before voting.
Voting matters and shareholder proposals
Election of 11 director nominees is on the ballot, with board recommending a vote for all.
Ratification of the appointment of the independent registered public accounting firm is proposed.
Advisory approval of executive compensation (say-on-pay) is included.
Proxy holders may vote on any other matters that arise during the meeting.
Board of directors and corporate governance
Eleven individuals are nominated for election to the board, including Andrés Conesa, Pablo A. Ferrero, Jennifer M. Kirk, and others.
Latest events from Sempra
- $65B capital plan and record adjusted EPS drive sector-leading growth outlook.SRE
Q4 202526 Feb 2026 - Q2 2024 earnings rose to $713M, with strong Texas/California growth and major projects advancing.SRE
Q2 20242 Feb 2026 - Q3 EPS fell, but guidance and $3B equity plan reaffirmed; Texas and LNG drive growth.SRE
Q3 202416 Jan 2026 - Q1 2025 EPS up, guidance affirmed, and major asset sales and capital investment drive outlook.SRE
Q1 20258 Jan 2026 - 2024 adjusted EPS hit $4.65, with a $56B capital plan and 7–9% EPS growth targeted.SRE
Q4 20247 Jan 2026 - Board refreshment, performance-based pay, and ambitious ESG targets headline the 2025 proxy.SRE
Proxy Filing1 Dec 2025 - Director nominee Jennifer M. Kirk will become CEO of Exubrion Therapeutics in May 2025.SRE
Proxy Filing1 Dec 2025 - Q2 2025 adjusted EPS held steady as utility growth, LNG progress, and guidance advanced.SRE
Q2 202523 Nov 2025 - Adjusted EPS up, major asset sale and Texas/LNG growth drive strong long-term outlook.SRE
Q3 20255 Nov 2025